Status:
RECRUITING
Ketamine for Multiple Sclerosis Fatigue
Lead Sponsor:
Johns Hopkins University
Collaborating Sponsors:
United States Department of Defense
Conditions:
Multiple Sclerosis Fatigue
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The proposed study is a single-center, phase II, randomized, double-blind, parallel-group, active-placebo-controlled trial of intravenous low-dose ketamine in patients with MS fatigue.
Eligibility Criteria
Inclusion
- Subject must be a man or woman, 18 to 65 years of age, inclusive.
- Subject must be medically stable based on physical examination, medical history, and vital signs
- Subject must meet McDonald 2017 diagnostic criteria for multiple sclerosis based on the PI review of the medical records
- Subject must complain from fatigue as one of their main symptoms and have a screening MFIS score equal or higher than the cutoff based on gender, age, and education displayed in Table-226
- Subject must be ambulatory (able to walk at least 20 feet using bilateral assistance)
- Subject must have internet and email access and ability to use a computer or tablet or smartphone
- Subjects that are currently taking medication for alleviating fatigue (such as amantadine, modafinil and armodafinil, and amphetamine-like psychostimulants) at Screening are eligible to participate unless the medication is one of the disallowed therapies (Table 3). Subjects taking a fatigue medication at the Screening visit must have been receiving a stable dose for at least four weeks before the Screening visit and be willing to continue the medication at the same dose for the duration of the study.
Exclusion
- BDI-II score of more than 29 (indicating severe depression)
- Having a known clear cause for secondary fatigue, such as untreated sleep apnea, untreated hypothyroidism, chronic liver disease, history of moderate to severe anemia (hemoglobin concentration of less than 9 gr/dl in men or less than 8 gr/dl in women).
- Neurodegenerative disorders other than relapsing or progressive MS
- Breastfeeding or pregnant
- History of coronary artery disease or congestive heart failure
- Uncontrolled hypertension at Screening (history of high blood pressure and screening systolic blood pressure \>160 or diastolic blood pressure\>100)
- History of severe liver disease, including cirrhosis
- Terminal medical conditions
- Currently treated for active malignancy
- Alcohol or substance abuse in the past year (except marijuana or other cannabinoids)
- A history of intolerance or allergic or anaphylactic reaction to ketamine or midazolam
- Clinically unstable medical or psychiatric disorders that require acute treatment as determined by the PI
- History of severe or untreated coronary artery disease or history of congestive heart failure
- History of prior ischemic or hemorrhagic stroke and cerebral vascular aneurysms.
- History of recurrent seizures or epilepsy
- Taking any disallowed therapy(ies), as noted in the protocol.
Key Trial Info
Start Date :
January 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT05378100
Start Date
January 1 2023
End Date
October 1 2026
Last Update
December 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University
Baltimore, Maryland, United States, 21287